Buy Now
$4,123 $4,850
15% off
$4,840 $6,050
20% off
$5,845 $8,350
30% off
Buy now
Premium Report Details
Base Year: 2024
Companies covered: 12
Tables & Figures: 272
Countries covered: 19
Pages: 150
Download Free PDF

Travel Vaccines Market
Get a free sample of this reportGet a free sample of this report Travel Vaccines Market
Is your requirement urgent? Please give us your business email for a speedy delivery!
Travel Vaccines Market Size
The global travel vaccines market was estimated at USD 4.9 billion in 2024. The market is expected to grow from USD 5.2 billion in 2025 to USD 12.1 billion in 2034, growing at a CAGR of 9.9%. The market is poised for significant growth, driven by combination of global health trends, technological advancements and shifting travel patterns.
The growing awareness for region-specific infectious diseases and the importance of preventive measures is driving higher demand for immunization prior to travel. This heightened awareness is further reinforced by digital health platforms, government healthcare initiatives, and educational campaigns, positioning travel vaccines as a fundamental aspect of pre-travel planning and boosting market demand.
Travel vaccines are preventive immunization designed to protect individuals from infectious disease such as Hepatitis, yellow fever, typhoid, rabies, and other regions specific diseases. Major players in the industry include GlaxoSmithKline plc (GSK), Sanofi, Pfizer, and Merck, among others. These companies are leveraging innovation in vaccine technology, and global reach responding to emerging infectious threats.
The market substantially increased from USD 3.7 billion in 2021 to USD 4.4 billion in 2023. While growth during the pandemic was subdued due to widespread lockdowns and travel restrictions that limited exposure to infectious agents, the post-pandemic resurgence in outbound travel has reignited demand for travel-related immunization. The reopening of international borders and the rebound of tourism and business travel have led more travelers to proactively prioritize health precautions, especially for regions with endemic diseases.
According to the United Nations World Tourism Organization (UNWTO), Italy saw a sharp rise in tourist arrivals, from 38.42 million in 2020 and 40.19 million in 2021 to 74.32 million in 2022. This rebound in international travel is expected to accelerate the demand for travel-specific vaccines, reversing the earlier decline and supporting a steady market recovery
Advancements in vaccines development, such as single-dose formulations, mRNA technology, scalable manufacturing processes and improved cold-chain logistics, are streamlining production and distribution, enhancing global accessibility. These innovations are particularly impactful in developing regions, where improved vaccine access can significantly broaden market reach.
The travel vaccine market is categorized into mono vaccine and combination vaccines, distributed through public and private channels. These vaccines are essential in mitigating health risks associated with both international and domestic travel, especially to destinations with poor sanitation or high disease prevalence.
Travel Vaccines Market Trends
Travel Vaccines Market Analysis
The global market was valued at USD 3.7 billion in 2021. The market size reached USD 4.4 billion in 2023, from USD 4.1 billion in 2022.
Based on the vaccine type, the market is segmented into mono vaccines and combination vaccines. The mono vaccines segment accounted for the largest revenue of USD 2.9 billion in 2024 due to their targeted protection against specific diseases that are commonly prevalent in travel destinations. The segment is expected to exceed USD 7.1 billion by 2034, growing at a CAGR of 9.7% during the forecast period.
Based on the disease type, the travel vaccines market is segmented into hepatitis A, meningococcal diseases, influenza, diphtheria, pertussis, tetanus (DPT), rabies, yellow fever, typhoid, measles, mumps, and rubella (MMR), Hepatitis B, and other disease types. The Hepatitis A vaccine segment accounted for the largest market share of 20.2% in 2024, reflecting its critical role in preventing one of the most common vaccine-preventable travel-related infections. The high incidence of Hepatitis A in popular travel destinations, particularly across Asia, Africa, and Latin America, continues to drive robust demand among outbound and domestic travelers.
Based on application, the travel vaccines market is segmented into outbound travel and domestic travel. The outbound travel segment accounted for the highest market share in 2024 and is expected to reach USD 7.9 billion by 2034, driven by heightened exposure to infectious diseases in international destinations, particularly in developing regions with lower public health infrastructure.
Based on the age group, the travel vaccines market is segmented into pediatric and adult. The adult segment accounted for the highest market share of 73.4% in 2024, primarily due to the high volume of adult travelers undertaking both leisure and business trips across domestic and international destinations. This demographic is expected to continue driving the majority of vaccine demand through the forecast period.
Based on the end use, the travel vaccines market is segmented into online channel and offline channel. The hospital segment dominated the market in 2024, generating the highest revenue of USD 2.4 billion, driven by the widespread availability of comprehensive immunization services and access to experienced medical professionals.
North America dominated the global travel vaccines market with the highest market share of 43.9% in 2024.
In 2024, U.S. market accounted for USD 1.9 billion revenue from USD 1.8 billion in 2023 and is anticipated to grow at a CAGR of 9.3% between the 2025 to 2034 period.
Germany is poised to achieve significant growth in the Europe travel vaccines market.
Asia Pacific is poised to grow at a significant growth rate in the global travel vaccines market over the next few years.
Brazil is projected to witness significant growth in Latin America travel vaccines market in coming years.
Saudi Arabia is anticipated to grow in the Middle East and Africa travel vaccines market.
Travel Vaccines Market Share
The leading companies such as GlaxoSmithKline plc (GSK), Sanofi, Pfizer, CSL and Merck hold 72% of the market share. These companies are shaping the competitive landscape through robust R&D capabilities, strategic partnership and expanding distribution network. The companies are continuously striving to expand their capabilities to offer comprehensive vaccines such as typhoid vaccines, Hepatitis A and Hepatitis B vaccines, yellow fever and Japana encephalitis vaccines that are crucial for domestic as well as outbound travelers to high-risk regions.
The emerging players such as Valneva, Bavarian Nordic and Serum Institute of India are gaining traction through niche innovation such as vaccines for chikungunya and Japanese encephalitis. Further, Serum Institute of India is expanding vaccines reach by offering cost-effective solutions along with strategic distribution partnerships to Asian market.
Travel Vaccines Market Companies
Few of the prominent players operating in the travel vaccines industry include:
GSK offers a robust portfolio of travel vaccines including Havrix (Hepatitis A) and Typherix (typhoid). Its innovation in combination vaccines and strategic partnerships with governments and travel clinics, combined with its extensive distribution network enhance its global reach and market position.
Sanofi leadership is indicated from its expertise in travel-related diseases, offering vaccines for rabies, typhoid and yellow fever. The company leverages advanced R&D capabilities, manufacturing, and advanced cold-chain distribution service for medicines and vaccines, ensuring its reliability and global accessibility to its vaccine portfolio. Additionally, its global presence and focus on underserved regions enhances its influence in the travel health sector.
Merck offer comprehensive vaccine, including DPT, MMR, and hepatitis vaccines. Its well-stated regulatory approvals, investment in vaccine technology, and public-private collaborations help it sustain high demand among travelers and global health programs.
Pfizer is well known for its pioneering vaccine technologies and extensive distribution capabilities. Its travel vaccines benefit from cutting-edge research and high efficacy standards. Pfizer’s stands for rapid innovation, particularly post-COVID, and its strong regulatory compliance make it a preferred choice for travelers and healthcare providers worldwide.
Travel Vaccines Industry News:
The travel vaccines market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2021 – 2034 for the following segments:
Click here to Buy Section of this Report
Market, By Vaccine Type
Market, By Disease Type
Market, By Application
Market, By Age Group
Market, By End Use
The above information is provided for the following regions and countries: